Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blue Jet HealthcareBOM:544009 +0.86%64 EBITDA Margin % is 40.14% as of Mar. 2026, which is 3% above its 10-year median of 38.92. GuruFocus rates BOM:544009 with a GF Score™ of 64/100 and a GF Value™ of ₹562.05 (Fairly Valued). The stock has 10 warning signs investors should review. Among 940 Biotechnology companies, Blue Jet Healthcare ranks better than 91.49% on this metric.
Blue Jet Healthcare (BOM:544009) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Blue Jet Healthcare EBITDA Margin % Related Terms
Blue Jet Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Blue Jet Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544009 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Blue Jet Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blue Jet Healthcare EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Blue Jet Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Blue Jet Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blue Jet Healthcare (BOM:544009) has a EBITDA Margin % of 40.14% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Blue Jet Healthcare and its competitors. This is near median its historical median of 38.92. Over the past decade, Blue Jet Healthcare's EBITDA Margin % has ranged from 33.73 to 42.16. According to the industry distribution chart, Blue Jet Healthcare ranks #80 out of 940 companies in the Biotechnology industry, placing it in the top 8.5%.
Is Blue Jet Healthcare's EBITDA Margin % too high?
Blue Jet Healthcare's current EBITDA Margin % of 40.14% is near median its 10-year median of 38.92. Over the past 10 years, this metric has ranged from a low of 33.73 to a high of 42.16. Based on the distribution chart, Blue Jet Healthcare ranks #80 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Blue Jet Healthcare has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Blue Jet Healthcare's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Blue Jet Healthcare ranks #80 out of 940 companies for EBITDA Margin %. This places Blue Jet Healthcare in the top 9% of its industry — outperforming the majority of peers. Historically, Blue Jet Healthcare's own EBITDA Margin % has ranged from 33.73 to 42.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Blue Jet Healthcare and its competitors. Blue Jet Healthcare's current EBITDA Margin % is 40.14%, which is near median its own 10-year median of 38.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blue Jet Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Blue Jet Healthcare (BOM:544009) is currently considered Fairly Valued. The stock's GF Value™ is ₹562.05, compared to a current price of ₹589.75 — trading 4.9% above its estimated fair value. The current EBITDA Margin % is 40.14%, which is near median its 10-year median of 38.92. Blue Jet Healthcare's overall GF Score™ is 64/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Blue Jet Healthcare (BOM:544009), the current EBITDA Margin % is 40.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blue Jet Healthcare (BOM:544009) Overvalued in 2026?
Based on GuruFocus' analysis, Blue Jet Healthcare stock appears to be overvalued.
The current stock price of ₹589.75 is trading 4.9% above its estimated GF Value™ of ₹562.05.
GuruFocus considers Blue Jet Healthcare to be Fairly Valued.
Key valuation signals for BOM:544009:
EBITDA Margin %: 40.14% (near median its 10-year median of 38.92)
GF Value™: ₹562.05 vs. price of ₹589.75 (4.9% above fair value)
No single metric tells the full story. See the BOM:544009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blue Jet Healthcare Ltd is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare Products. The operations of the company are organized in three product categories which are contrast media intermediates, artificial sweeteners, pharma intermediates, and active pharmaceutical ingredients. Geographically, it operates in Norway, France, India and Rest of the World.
64GF Score
Get the complete analysis for BOM:544009
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544009 has been successfully added to your 
